Implementation of the asparaginase activity assessment technique for clinical use: experience of a Brazilian Center

Author:

Cecconello Daiane Keller,Rechenmacher Ciliana,Werlang Isabel,Zenatti Priscila Pini,Yunes Jose Andres,Alegretti Ana Paula,Lanvers-Kaminsky Claudia,Daudt Liane Esteves,Michalowski Mariana Bohns

Abstract

AbstractAcute lymphoid leukemia is a childhood cancer that in high-income countries has event-free survival rates of 80% and global survival rates of 90%. In Brazil these rates are under 70%. This difference may be due to the implementation of supportive care, including the assessment of asparaginase (ASNase) activity. ASNase may cause hypersensitivity reactions and silent drug inactivation. For this reason, ASNase activity monitoring is an essential tool to ensure an effective treatment. Our aim was to implement an ASNase activity measurement technique at a hospital setting. samples from children who were given Escherichia coli-derived ASNase were collected. The results of the analyses conducted in our laboratory Hospital de Clínicas de Porto Alegre were compared to those of two institutions: Centro Infantil Boldrini and University of Munster. 262 samples were assessed. The results of the first analyses were compared with those obtained at Centro Infantil Boldrini and showed an ICC of 0.954. Thirty samples were sent to the University of Munster and presented an ICC was 0.960. Our results, when compared to those of national and international centers, showed an excellent agreement. The study was able to implement an ASNase activity test to monitor the treatment.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Reference27 articles.

1. Pieters, R. et al. l-Asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 102, 238–249 (2012).

2. Asselin, B. et al. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leukemia Lymphoma 56, 2273–2280 (2015).

3. Avramis, V. I. & Tiwari, P. N. Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. Int. J. Nanomed. 1, 241–254 (2006).

4. Schrey, D. et al. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007. Pediatr. Blood Cancer. 54, 952–958 (2010).

5. Rizzari, C. et al. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr. Opin. Oncol. 25, S1–S9 (2013).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3